Intrapleural administration of lipoplatin in an animal model

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 78-83

  Froudarakis, Marios E ^a,b   Greillier, Laurent ^b   Monjanel Mouterde, Suzanne ^b,c   Koutsopoulos, Anastassios ^a   Devictor Pierre, Benedicte ^a,b,c   Guilhaumou, Romain ^a,b,c   Karpathiou, Georgia ^a   Botaitis, Sotirios ^a   Astoul, Philippe ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Animal; Histology; Intrapleural treatment; Lipoplatin; Lung cancer; Mesothelioma; Pharmacokinetics; Pleura; Thoracoscopy

Indexed keywords

CISPLATIN; LIPOPLATIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; HISTOPATHOLOGY; KIDNEY INJURY; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLEURISY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CISPLATIN; DISEASE MODELS, ANIMAL; INJECTIONS; KIDNEY; LUNG; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 79952190160     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.010     Document Type: Article

References (33)

1. Froudarakis M.E. Diagnostic work-up of pleural effusions. Respiration 2008, 75(1):4-13.
2. Barbieri V., Tassone P., Tagliaferri P. The IASLC lung cancer staging project: revision proposal of pleural effusion and controlateral nodule staging. J Thorac Oncol 2008, 3(3 (March)):317. [author reply-8].
3. Barlesi F., Pujol J.L. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer 2005, 49(3 (September)):289-298.
4. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998, 34(10):1535-1542.
5. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22(19 (October)):3852-3859.
6. Ismail-Khan R., Robinson L.A., Williams C.C.J., Garrett C.R., Bepler G., Simon G.R. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006, 13:255-263.
7. Robinson B.W.S., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
8. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14 (July)):2636-2644.
9. Rinaldi D.A., Burris H.A., Dorr F.A., Woodworth J.R., Kuhn J.G., Eckardt J.R., et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor. LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995, 13(11 (November)):2842-2850.
10. Takimoto C.H. Antifolates in clinical development. Semin Oncol 1997, 24(5 Suppl. 18 (October)). S18-40-51.
11. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts. Oncol Rep 2004, 12(1 (July)):3-12.
12. Boulikas T., Stathopoulos G.P., Volakakis N., Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005, 25(4 (July-August)):3031-3039.
13. Stathopoulos G.P., Boulikas T., Vougiouka M., Deliconstantinos G., Rigatos S., Darli E., et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (lipoplatin): phase I study. Oncol Rep 2005, 13(4 (April)):589-595.
14. Froudarakis M.E., Pataka A., Pappas P., Anevlavis S., Argiana E., Nikolaidou M., et al. Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer 2008, 113(10 (November)):2752-2760.
15. Karpathiou G., Argiana E., Koutsopoulos A., Froudarakis M.E. Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine. Oncology 2007, 73(5-6):426-429.
16. Dedrick R.L., Myers C.E., Bungay P.M., DeVita V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978, 62(1 (January)):1-11.
17. Markman M. Intracavitary chemotherapy. Curr Probl Cancer 1986, 10(8 (August)):401-437.
18. Monjanel-Mouterde S., Frenay C., Catalin J., Boutin C., Durand A., Astoul P. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions. Oncol Rep 2000, 7(1 (January-February)):171-175.
19. Lerza R., Vannozzi M.O., Tolino G., Viale M., Bottino G.B., Bogliolo G., et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol 1997, 8(4 (April)):385-391.
20. Holoye P.Y., Jeffries D.G., Dhingra H.M., Holmes F.A., Raber M., Engineer M.S., et al. Intrapleural etoposide for malignant effusion. Cancer Chemother Pharmacol 1990, 26(2):147-150.
21. Perng R.P., Wu M.F., Lin S.Y., Chen Y.M., Lin J.Y., Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs 1997, 8(6 (July)):565-573.
22. Greillier L., Monjanel-Mouterde S., Fraticelli A., Devictor-Pierre B., Bouvenot J., Coltel N., et al. Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. J Thorac Oncol 2009, 4(3 (March)):404-408.
23. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966, 50(4 (May)):219-244.
24. Perez-Soler R., Shin D.M., Siddik Z.H., Murphy W.K., Huber M., Lee S.J., et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997, 3(3 (March)):373-379.
25. Iliadis A., Brown A.C., Huggins M.L. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 1992, 38(4 (August)):227-239.
26. Nishina K., Mikawa K., Takao Y., Shiga M., Maekawa N., Obara H. Intravenous lidocaine attenuates acute lung injury induced by hydrochloric acid aspiration in rabbits. Anesthesiology 1998, 88(5 (May)):1300-1309.
27. Colt H.G., Russack V., Chiu Y., Konopka R.G., Chiles P.G., Pedersen C.A., et al. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. Chest 1997, 111(2 (February)):442-448.
28. Vadiei K., Siddik Z.H., Khokhar A.R., al-Baker S., Sampedro F., Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992, 30(5):365-369.
29. Astoul P., Bertault-Peres P., Durand A., Catalin J., Vignal F., Boutin C. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer 1994, 73(2 (January)):308-313.
30. Lu C., Perez-Soler R., Piperdi B., Walsh G.L., Swisher S.G., Smythe W.R., et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005, 23(15 (May)):3495-3501.
31. Seto T., Ushijima S., Yamamoto H., Ito K., Araki J., Inoue Y., et al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 2006, 95(6 (September)):717-721.
32. Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009, 18(8 (August)):1197-1218.
33. Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007, 109(4 (February)):692-702.